DW
DWTX.US Dogwood Therapeutics, Inc.
- Market cap
- USD 42.4M
- P/E
- 0.1x
- P/B
- 0.66x
- ROE
- -44.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is DWTX.US undervalued?
Graham numberThe Graham number of Dogwood Therapeutics, Inc. cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Dogwood Therapeutics, Inc. fundamental analysis
No fundamental analysis for Dogwood Therapeutics, Inc. yet.
Dogwood Therapeutics, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Dogwood Therapeutics, Inc.
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-induced neuropathic pain and cancer pain, as well as pre-clinical trial for acute surgical …
Full company profileDogwood Therapeutics, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Dogwood Therapeutics, Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 133K |
| Gross Profit | - | - | - | - | - | - | -12.2K | - | - |
| Operating Income | -1.96M | -2.18M | -10.0M | -15.6M | -12.3M | -5.45M | -12.2M | -28.0M | -19.8M |
| EBITDA | -1.96M | -2.18M | -10.0M | -16.0M | -12.2M | -5.30M | -12.2M | -34.0M | -19.6M |
| Net Income | -2.11M | -2.47M | -10.3M | -16.0M | -12.2M | -5.30M | -12.3M | -34.3M | -28.5M |
| EPS | -11 | -13 | -52 | -48 | -28 | -7.05 | -12 | -4.17 | -0.84 |
| Balance Sheet | |||||||||
| Total Assets | 65.9K | 316K | 31.5M | 15.8M | 8.37M | 4.17M | 94.3M | 90.2M | 75.6M |
| Total Liabilities | 1.33M | 5.26M | 1.53M | 1.28M | 1.04M | 359K | 30.0M | 15.3M | 11.5M |
| Shareholders' Equity | -1.26M | -4.94M | 29.9M | 14.5M | 7.33M | 3.81M | 64.3M | 74.9M | 64.1M |
| Cash & Short-term Investments | 30.0K | 309K | 29.8M | 14.0M | 7.03M | 3.32M | 14.8M | 6.52M | 4.95M |
| Total Debt | - | 3.64M | - | - | - | - | 15.6M | 163K | 118K |
| Cash Flow | |||||||||
| Operating Cash Flow | -1.20M | -2.09M | -3.90M | -15.7M | -11.5M | -4.87M | -8.79M | -15.6M | -17.1M |
| Capital Expenditure | 0.00 | 0.00 | 5.00 | 0.00 | 3.00 | 0.00 | 5.00 | 0.00 | 16.00 |
| Free Cash Flow | -1.20M | -2.09M | -3.90M | -15.7M | -11.5M | -4.87M | -8.79M | -15.6M | -17.1M |
| Ratios | |||||||||
| ROE | - | - | -34.6% | -110.1% | -167.2% | -139.1% | -19.2% | -45.7% | -44.5% |
| ROA | -3,205.6% | -783.0% | -32.9% | -101.2% | -146.3% | -127.1% | -13.1% | -38.0% | -37.7% |
| Net Profit Margin | - | - | - | - | - | - | - | - | -21,399.2% |
| Debt to Equity | - | - | - | - | - | - | 0.24x | 0.00x | 0.00x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Dogwood Therapeutics, Inc. dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | USD 75.0K | 0.38 | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:25 on Oct 9, 2024.
Who owns Dogwood Therapeutics, Inc.
- Insiders 84.63%
- Institutions 11.47%
- Public & others 3.90%
- Shares outstanding 38.2M
- Free float 1.71M
Top funds holding DWTX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Extended Market Index | 56.5K | 0.15% | -0.38% | Sep 2026 |
| iShares Micro-Cap ETF | 24.2K | 0.06% | 0.00% | Oct 2026 |
| Fidelity Series Total Market Index | 13.1K | 0.03% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 4.59K | 0.01% | 0.00% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 3.77K | 0.01% | 0.00% | Aug 2026 |
| 1290 VT Micro Cap K | 1.89K | 0.00% | 0.00% | Sep 2026 |
Top institutions holding DWTX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Armistice Capital, LLC | 3.13M | 9.22% | -4.50% | Jun 2026 |
| Millennium Management LLC | 342K | 1.01% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 132K | 0.39% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 88.3K | 0.26% | +11.16% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 62.7K | 0.18% | 0.00% | Jun 2026 |
| BlackRock Inc | 28.5K | 0.08% | +95,053.33% | Jun 2026 |
| Northern Trust Corp | 23.8K | 0.07% | 0.00% | Jun 2026 |
| Citadel Advisors Llc | 11.7K | 0.03% | 0.00% | Jun 2026 |
| Tower Research Capital LLC | 3.09K | 0.01% | -61.66% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 2.22K | 0.01% | 0.00% | Jun 2026 |
| UBS Group AG | 1.86K | 0.01% | -73.75% | Jun 2026 |
| Mercer Global Advisors Inc. | 550.00 | 0.00% | 0.00% | Jun 2026 |
| JONES FINANCIAL COMPANIES LLLP | 160.00 | 0.00% | 0.00% | Jun 2026 |
| Barclays PLC | 157.00 | 0.00% | 0.00% | Jun 2026 |
| Activest Wealth Management | 120.00 | 0.00% | 0.00% | Jun 2026 |
| Group One Trading, LLC | 9.00 | 0.00% | 0.00% | Jun 2026 |
| The Goldman Sachs Group Inc | 0.00 | 0.00% | -100.00% | Jun 2026 |
| BNP Paribas Arbitrage, SA | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 0.00 | 0.00% | -100.00% | Jun 2026 |
Dogwood Therapeutics, Inc. company profile
- Company name
- Dogwood Therapeutics, Inc.
- Ticker
- DWTX.US
- Exchange
- USA Stocks
- Listed since
- Dec 17, 2020
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 8
- Fiscal year end
- December
- Address
- 44 Milton Avenue, Alpharetta, GA, United States, 30009
- Phone
- 866 620 8655
- Website
- dwtx.com
About Dogwood Therapeutics, Inc.
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-induced neuropathic pain and cancer pain, as well as pre-clinical trial for acute surgical pain; and IMC-2, a combination of valacyclovir and celecoxib intended to synergistically suppress herpesvirus activation; and Serpin Peptide 16 that is in early Phase 1 development to reduce neuropathy secondary to treat chemotherapeutic agents that are neurotoxic. The company was formerly known as Virios Therapeutics, Inc. and changed its name to Dogwood Therapeutics, Inc. in October 2024. The company was founded in 2012 and is based in Alpharetta, Georgia.
Dogwood Therapeutics, Inc. management
6- Mr. Gregory DuncanChairman & CEO · born 1965
- Ms. Angela WalshCFO, Secretary & Treasurer · born 1967
- Dr. R. Michael Gendreau M.D., Ph.D.Chief Medical Officer · born 1956
- Dr. William L. Pridgen M.D.Founder & Member of Scientific Advisory Board · born 1961
- Mr. Ralph D. Grosswald M.P.H.Senior Vice President of Operations · born 1969
- Ms. Carol Duffy Ph.D.Chief Scientific Advisor